Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
MaxCyte ( (MXCT) ) has issued an announcement.
On August 6, 2025, MaxCyte reported its financial results for the second quarter of 2025, highlighting a total revenue of $8.5 million, an 18% decrease from the previous year. Despite facing short-term challenges, including a reduction in SPL Program-related revenue and a net loss of $12.4 million, MaxCyte remains optimistic about its position in the cell and gene therapy industry. The company has adjusted its 2025 guidance to reflect current market conditions and continues to focus on operational efficiencies and product enhancements.
The most recent analyst rating on (MXCT) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on MaxCyte stock, see the MXCT Stock Forecast page.
Spark’s Take on MXCT Stock
According to Spark, TipRanks’ AI Analyst, MXCT is a Neutral.
MaxCyte’s financial challenges and valuation concerns weigh heavily on the stock’s score. However, strong shareholder support, strategic plans, and a solid cash position provide a basis for potential recovery, especially if operational efficiencies improve and macroeconomic conditions stabilize.
To see Spark’s full report on MXCT stock, click here.
More about MaxCyte
MaxCyte is a leading cell-engineering company that focuses on the discovery, development, and commercialization of next-generation cell therapies. The company offers Flow Electroporation technology and SeQure DX gene editing risk assessment services, enabling precise and scalable cell engineering to advance human health treatments.
Average Trading Volume: 845,410
Technical Sentiment Signal: Sell
Current Market Cap: $219M
See more insights into MXCT stock on TipRanks’ Stock Analysis page.